Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -437.97% is in line with its 5-year average of -461.06%, around the middle of its 5-year range (-2099.65%–495.59%).
27.48% above its 12-month average of -603.94%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 495.59%.
EBITDA MARGIN
-437.97%
EBITDA MARGIN AVG TTM
-603.94%
EBITDA MARGIN AVG 3Y
-453.50%
EBITDA MARGIN AVG 5Y
-461.06%
EBITDA MARGIN AVG 10Y
-370.73%
EBITDA MARGIN AVG 15Y
-398.14%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+27.48%
CURRENT VS 3Y AVG
+3.42%
CURRENT VS 5Y AVG
+5.01%
CURRENT VS 10Y AVG
-18.14%
CURRENT VS 15Y AVG
-10.00%
CURRENT VS 20Y AVG
N/A
IceCure Medical Ltd
Market Cap
$3.15M
EBITDA Margin
-437.97%
TTM Avg
-603.94%
3Y Avg
-453.50%
5Y Avg
-461.06%
Market Cap
$3.14M
EBITDA Margin
-4291.67%
TTM Avg
-3563.06%
3Y Avg
-8274.29%
5Y Avg
-15578.54%
Market Cap
$3.23M
EBITDA Margin
-2030.10%
TTM Avg
-2765.29%
3Y Avg
-1907.45%
5Y Avg
-2238.98%
Market Cap
$3.02M
EBITDA Margin
-22711.52%
TTM Avg
-15924.10%
3Y Avg
-12940.13%
5Y Avg
-12940.13%
Market Cap
$3.32M
EBITDA Margin
-7.62%
TTM Avg
-1345.01%
3Y Avg
-903.09%
5Y Avg
-551.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IceCure Medical Ltd (ICCM) | $3.15M | -437.97% | -603.94% | -453.50% | -461.06% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | -4291.67% | -3563.06% | -8274.29% | -15578.54% |
| MBody AI Ltd. (MBAI)vs › | $3.17M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.23M | -2030.10% | -2765.29% | -1907.45% | -2238.98% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.02M | -22711.52% | -15924.10% | -12940.13% | -12940.13% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.32M | -7.62% | -1345.01% | -903.09% | -551.32% |
| Revelation Biosciences, Inc. (REVB)vs › | $2.94M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.54M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.49M | 3.53% | -69.60% | -286.97% | -286.97% |
Gross Margin
36.1%
EBITDA Margin
-438.0%
Operating Margin
-446.7%
Net Margin
-427.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 495.59% |
| 2026-03-31 | -458.62% |
| 2025-12-31 | -324.08% |
| 2025-09-30 | -2099.65% |
| 2025-06-30 | -632.95% |
| 2025-03-31 | -492.14% |
| 2024-12-31 | -507.77% |
| 2024-09-30 | -635.95% |
| 2024-06-30 | -311.18% |
| 2024-03-31 | -479.91% |
| 2023-12-31 | -265.15% |
| 2023-09-30 | -1236.29% |
| 2023-06-30 | -427.25% |
| 2023-03-31 | -546.41% |
| 2022-12-31 | -410.86% |
| 2022-09-30 | -635.80% |
| 2022-06-30 | -552.81% |
| 2022-03-31 | -585.41% |
| 2021-12-31 | -223.05% |
| 2021-09-30 | -413.22% |
| 2021-06-30 | -396.55% |
| 2021-03-31 | -81.48% |
| 2020-12-31 | -84.18% |
| 2020-09-30 | -208.82% |
| 2020-06-30 | -85.88% |
| 2020-03-31 | -85.88% |
| 2019-12-31 | -200.38% |
| 2019-09-30 | -200.38% |
| 2019-06-30 | -406.95% |
| 2019-03-31 | -406.95% |
| 2018-12-31 | -272.30% |
| 2018-09-30 | -281.05% |
| 2018-06-30 | -316.04% |
| 2018-03-31 | -316.04% |
| 2017-12-31 | -1097.54% |
| 2017-09-30 | -398.51% |
| 2017-06-30 | -282.23% |
| 2017-03-31 | -282.23% |
| 2016-12-31 | -775.87% |
| 2016-09-30 | -260.37% |
| 2016-06-30 | -472.21% |
| 2016-03-31 | -610.45% |
| 2015-12-31 | -267.75% |
| 2015-09-30 | -575.24% |
| 2015-06-30 | -614.93% |
| 2015-03-31 | -469.53% |
| 2014-12-31 | -241.62% |
| 2014-09-30 | -312.83% |
| 2014-06-30 | -320.71% |
| 2014-03-31 | -1753.01% |
| 2013-12-31 | -1198.98% |
| 2013-09-30 | -485.34% |
| 2013-06-30 | -1444.92% |
| 2013-03-31 | -1783.45% |
| 2012-12-31 | -2048.79% |
| 2012-09-30 | -1210.34% |
